Research Paper Volume 12, Issue 24 pp 25275—25293
DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications
Figure 8. Identification of novel candidate drugs targeting methylation signatures.